B02
Modify Date: 2024-01-05 09:49:29
B02 structure
|
Common Name | B02 | ||
|---|---|---|---|---|
| CAS Number | 1290541-46-6 | Molecular Weight | 339.39000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H17N3O | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of B02RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM. |
| Name | (E)-3-benzyl-2-(2-(pyridin-3-yl)vinyl)quinazolin-4(3H)-one |
|---|---|
| Synonym | More Synonyms |
| Description | RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 27.4 μM (hRAD51)[1] |
| In Vitro | RAD51 Inhibitor B02 specifically inhibits human RAD51 (IC50=27.4 μM), but not its E. coli homologue RecA (IC50>250 μM)[1]. The combination of B02 with cisplatin has the strongest killing effect on the human breast cancer cells MDA-MB-231[2]. |
| In Vivo | B02 significantly enhances the therapeutic effect of cisplatin on tumor cells in vivo. B02 is tolerated by mice at doses up to 50 mg/kg without obvious body weight loss. No inhibition of tumor growth is observed on mice solely treated by B02. Mice treated with 4 mg/kg cisplatin, however, shows a 33% inhibition of tumor growth. Finally, mice treated with 50 mg/kg B02 and 4 mg/kg cisplatin shows a 66% inhibition of tumor growth[2]. |
| Cell Assay | The cells are exposed for 1 h, then the cells are ished by PBS three times and refreshed by the media containing B02 (5 µM). After 7-10 days, cells are fixed and stained with staining solution (0.05% crystal violet, 50% methanol in PBS); finally cell colonies are counted[2]. |
| Animal Admin | Mice: Cisplatin and B02 are dissolved in NS and cremophor/DMSO/NS (1:1:3) vehicle, respectively, immediately before injection. In a combination treatment group, the mice are injected with B02 (50 mg/kg or indicated otherwise) and cisplatin (4 mg/kg or indicated otherwise). In B02 group, mice are injected with B02 and NS; in cisplatin group, mice are injected with cisplatin and B02 vehicle. Cisplatin (or NS) is administrated 3 h after B02 (or its vehicle) injection. All the treatments are executed through I.P. injections on day 11, 13, 15 and 17 after tumor cells inoculations[2]. |
| References |
| Molecular Formula | C22H17N3O |
|---|---|
| Molecular Weight | 339.39000 |
| Exact Mass | 339.13700 |
| PSA | 47.78000 |
| LogP | 4.01020 |
| Storage condition | -20℃ |
|
A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage.
Oncogene 35 , 22-34, (2016) Fanconi anemia (FA) is a genetic disease of bone marrow failure, cancer susceptibility, and sensitivity to DNA crosslinking agents. FANCD2, the central protein of the FA pathway, is monoubiquitinated ... |
|
|
Survival of the replication checkpoint deficient cells requires MUS81-RAD52 function.
PLoS Genet. 9 , e1003910, (2013) In checkpoint-deficient cells, DNA double-strand breaks (DSBs) are produced during replication by the structure-specific endonuclease MUS81. The mechanism underlying MUS81-dependent cleavage, and the ... |
| (E)-3-BENZYL-2-(2-(PYRIDIN-3-YL)VINYL)QUINAZOLIN-4(3H)-ONE |
| 3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone |
| RAD51 inhibitor B02 |
| B02 |